SCHEMBL24540282

SCHEMBL24540282

O=C(O)CCC[C@H](NC(=O)N[C@@H](CCCCCNC(=O)[C@H](Cc1c2ccccc2cc2ccccc12)NC(=O)C1CCC(CNC(=O)CN(CCNCC(=O)O)CCN(CCNCC(=O)O)CC(=O)O)CC1)C(=O)O)C(=O)O

nearest known ligand 0.58

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ FOLH1 Q04609 19/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24540307 1.00 FOLH1 (0.58) FOLH1
SCHEMBL24540440 0.93 FOLH1 (0.51) FOLH1
SCHEMBL24540202 0.93 FOLH1 (0.51) FOLH1
SCHEMBL27022035 0.92 FOLH1 (0.52) FOLH1
SCHEMBL24540204 0.92 FOLH1 (0.51) FOLH1
SCHEMBL24540393 0.92 FOLH1 (0.49) FOLH1
SCHEMBL24540590 0.92 FOLH1 (0.51) FOLH1
SCHEMBL27022043 0.92 FOLH1 (0.51) FOLH1
SCHEMBL27022098 0.92 FOLH1 (0.52) FOLH1
SCHEMBL27021323 0.89 FOLH1 (0.51) FOLH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018110-A1 RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN ALPHA-9 ONCOLOGY INC. (CA) 2024-01-18 — — US disclosed
WO-2022126275-A1 RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2022-06-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018110-A1 RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN KLK3, FOLH1, TMEM14C FOLH1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback